Company news

Dyadic International, Inc. news in 2025

Dyadic International, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

December 17, 2025

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

December 15, 2025

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

December 1, 2025

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

November 12, 2025

ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement

November 10, 2025

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

November 10, 2025

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

October 29, 2025

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

October 6, 2025

Dyadic to Present at Investor Conferences and BPI East

September 4, 2025

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

August 13, 2025

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

August 5, 2025

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

July 31, 2025

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

July 31, 2025

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

July 30, 2025

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

July 2, 2025

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

June 2, 2025

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 14, 2025

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 1, 2025

Dyadic to Present at World Vaccine Congress | Washington

April 16, 2025

Dyadic Reports 2024 Year-End Financial Results and Business Updates

March 26, 2025

Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

March 20, 2025

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

March 12, 2025

Dyadic to Attend Multiple Industry Events in March

March 6, 2025

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025